Drug Trial Radar · NCT06032546
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
163
Actual
Start
Oct 12, 2023
Primary completion
Sep 22, 2025
Study completion Sep 22, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic disease requiring lifelong therapy. The purpose of this study is to assess change in disease activity, adverse events, tolerability, and how the drug moves through the body. Budigalimab and ABBV-382 are investigational drugs being developed for the treatment of HIV disease. In Part 1, participants are placed in 1 of 5 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 7 chance that participants will be assigned to placebo (A placebo is not a drug and it is not expected to have any chemical effects on your body and it is not designed to treat any disease or illness). In Part 2, eligible participants will be placed in an open-label arm to receive Budigalimab. Approximately 160 adult participants living with HIV disease on stable antiretroviral therapy (ART) willing to undergo Analytical Treatment Interruption (ATI) will be enrolled at approximately 90 sites worldwide. In Part 1, participants will receive 4 doses of intravenous (IV) budigalimab or placebo combined with 3 doses of IV ABBV-382 or placebo for an 8 week dosing period. In Part 2, participants will receive 4 doses of open-label subcutaneous (SC) Budigalimab for a 6 week dosing period. Participants need to be stable on antiretroviral therapy to participate in the study. If participant qualifies to the study, on the day they receive the first injection, participants will be asked to stop antiretroviral medications (also referred to as analytical treatment interruption or ATI) for 112 weeks or until meeting specific criteria to restart antiretroviral medications. Participants will undergo a closely monitored ART interruption. Protocol-defined ART restart criteria includes participant's request. Participants will be followed for up to approximately 112 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. There will be an option for virtual or home health visits for some of the follow-up visits. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Human Immuno-deficiency Virus (HIV) Disease
Interventions
BudigalimabDrug
Intravenous (IV) Infusion
Placebo for BudigalimabDrug
IV Infusion
ABBV-382Drug
IV Infusion
Placebo for ABBV-382Drug
IV Infusion
BudigalimabDrug
Subcutaneous (SC) Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Viral Control Without Antiretroviral Therapy (ART) RestartTime frame: Week 24
- Number of Participants With Adverse Events (AEs)Time frame: Up to approximately Week 112
Locations
80 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham, 1917 Research Clinic /ID# 257549
Birmingham, Alabama
Franco Felizarta, Md /Id# 256927
Bakersfield, California
AHF Research Center /ID# 257025
Beverly Hills, California
Long Beach Education and Research Consultants /ID# 257552
Long Beach, California
AHF Healthcare Center- Hollywood /ID# 257026
Los Angeles, California
Los Angeles LGBT Center /ID# 258407
Los Angeles, California
Ruane Clinical Research Group /ID# 256932
Los Angeles, California
Palmtree Clinical Research Inc. /Id# 258409
Palm Springs, California
Optimus Medical /ID# 257182
San Francisco, California
Quest Clinical Research /ID# 256928
San Francisco, California
Washington Health Institute /ID# 259336
Washington D.C., District of Columbia
Midland Florida Clinical Research Center /ID# 257101
DeLand, Florida
Ahf Healthcare Center - Northpoint /ID# 256934
Fort Lauderdale, Florida
Midway Immunology and Research Center /ID# 256930
Ft. Pierce, Florida
Advanced Pharma CR, LLC /ID# 259335
Miami, Florida
Orlando Immunology Center /ID# 256931
Orlando, Florida
Bliss Health /ID# 257827
Orlando, Florida
Baycare Medical Group - Tampa /ID# 256953
Tampa, Florida
The Pierone Research Institute /ID# 257022
Vero Beach, Florida
Triple O Research Institute /ID# 256929
West Palm Beach, Florida
Winship At Emory University Hospital Midtown /ID# 258410
Atlanta, Georgia
Metro Infectious Disease Consultants /ID# 256955
Decatur, Georgia
Howard Brown Health Center /ID# 257485
Chicago, Illinois
Claudia T. Martorell MD LLC dba The Research Institute /ID# 259155
Springfield, Massachusetts
KC CARE Health Center - Midtown South /ID# 257178
Kansas City, Missouri
Las Vegas Research Center /ID# 257619
Las Vegas, Nevada
Cooper University Health Care - Camden /ID# 258133
Camden, New Jersey
Saint Michael's Medical Center /ID# 258802
Newark, New Jersey
South Jersey Infectious Disease /ID# 257840
Somers Point, New Jersey
The University of New Mexico /ID# 257533
Albuquerque, New Mexico
Suny Upstate University Hospital Community Campus /ID# 257847
Syracuse, New York
Jacobi Medical Center /ID# 257849
The Bronx, New York
Montefiore Medical Center /ID# 257792
The Bronx, New York
East Carolina University - Brody School of Medicine /ID# 257544
Greenville, North Carolina
Atrium Health Wake Forest Baptist Medical Center /ID# 257542
Winston-Salem, North Carolina
Central Texas Clinical Research /ID# 256920
Austin, Texas
Prism Health North Texas - Oak Cliff Health Center /ID# 256933
Dallas, Texas
North Texas Infectious Diseases Consultants, P.A /ID# 257592
Dallas, Texas
University of Texas Southwestern Medical Center /ID# 257551
Dallas, Texas
Texas Center for Infectious Disease Associates /ID# 257183
Fort Worth, Texas
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.